FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 213 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Patient Guide on Immunotherapy Side Effects and Their Management Now Available... April 29, 2026 35-Year-Old Mom Has Been Living With Stage IV Breast Cancer For... March 25, 2020 A tribute to Professor Anne Charlton June 23, 2020 Financial Navigation Can Reduce the Financial Toxicity of Cancer Care April 21, 2023 Load more HOT NEWS 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... Epigenetic Changes Pinpointed as the Cause of Some GISTs
